EP2 and EP4 agonists as agents for the treatment of influenza a viral infection
The present invention is directed to the use of EP2 and/or EP4 agonists as therapeutics for the treatment of diseases associated with influenza A viruses, such as for example H5N1 and mutations thereof.
1. A method of treating an influenza A virus infection in a patient in need of such treatment, the method comprising administering to the patient an effective amount of a therapeutic agent selected from the group consisting of nileprost and beraprost.
2. The method of claim 1 , wherein said therapeutic agent is beraprost.
3. The method of claim 1 , wherein said therapeutic agent is nileprost.
4. The method of claim 1 , wherein the influenza A virus is H5N1 or a mutation thereof.
5. The method of claim 2 , wherein the influenza A virus is H5N1 or a mutation thereof.
6. The method of claim 3 , wherein the influenza A virus is H5N1 or a mutation thereof.
7. The method according to any one of claim 1 , 2 , 3 , 5 , or 6 , wherein said therapeutic agent inhibits the release of inflammatory cytokines and/or chemokines in human alveolar and bronchial epithelial cells.
8. The method of claim 2 , wherein said therapeutic agent inhibits the release of inflammatory cytokines and/or chemokines in human alveolar and bronchial epithelial cells.
9. The method of claim 3 , wherein said therapeutic agent inhibits the release of inflammatory cytokines and/or chemokines in human alveolar and bronchial epithelial cells.
10. The method of claim 4 , wherein said therapeutic agent inhibits the release of inflammatory cytokines and/or chemokines in human alveolar and bronchial epithelial cells.
11. The method of claim 5 , wherein said therapeutic agent inhibits the release of inflammatory cytokines and/or chemokines in human alveolar and bronchial epithelial cells.
12. The method of claim 6 , wherein said therapeutic agent inhibits the release of inflammatory cytokines and/or chemokines in human alveolar and bronchial epithelial cells.
13. The method of claim 1 , wherein said therapeutic agent inhibits the release of inflammatory cytokines and/or chemokines in peripheral blood lymphocytes.
14. The method of claim 2 , wherein said therapeutic agent inhibits the release of inflammatory cytokines and/or chemokines in peripheral blood lymphocytes.
15. The method of claim 3 , wherein said therapeutic agent inhibits the release of inflammatory cytokines and/or chemokines in peripheral blood lymphocytes.
16. The method of claim 4 , wherein said therapeutic agent inhibits the release of inflammatory cytokines and/or chemokines in peripheral blood lymphocytes.
17. The method of claim 5 , wherein said therapeutic agent inhibits the release of inflammatory cytokines and/or chemokines in peripheral blood lymphocytes.
18. The method of claim 6 , wherein said therapeutic agent inhibits the release of inflammatory cytokines and/or chemokines in peripheral blood lymphocytes.